EDEN
PRAIRIE, Minn., April 18,
2022 /PRNewswire/ -- NeuroOne Medical
Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the
"Company"), a medical technology company focused on improving
surgical care options and outcomes for patients suffering from
neurological disorders, today announced that it will present at
NobleCon18, Noble Capital Markets' 18th Annual Investor Conference
being held April 19-21, 2022.
NobleCon18
Conference
|
|
Presentation date and
time:
|
Thursday, April 21,
2022; 11:30 a.m. ET
|
Breakout
sessions:
|
Wednesday, April 20 at
1:45 p.m.; Thursday, April 21 at 1:00 p.m.
|
Location:
|
Hard Rock Hotel &
Casino, Hollywood, Florida
|
Registration:
|
Visit the conference
website
|
Webcast
replay:
|
Available beginning
April 22 for 90 days
|
NeuroOne Chief Executive Officer Dave
Rosa will discuss the Company's focus on the development and
commercialization of minimally invasive and
high-definition/high-precision solutions for epilepsy, Parkinson's
disease, dystonia, essential tremors, and chronic pain due to
failed back surgeries. These solutions include electrodes that have
the potential to reduce the number of hospitalizations and surgical
procedures, and reduce costs, while improving patient outcomes due
to their potential for offering combination diagnostic and
therapeutic functions such as EEG recording and tissue ablation
and/or chronic stimulation.
About NeuroOne® Medical Technologies
Corporation
NeuroOne is a medical technology company focused
on the development and commercialization of minimally invasive and
high-definition/high-precision solutions for epilepsy, Parkinson's
disease, dystonia, essential tremors, and chronic pain due to
failed back surgeries. A combination recording and RF
ablation technology is currently under development. In addition,
NeuroOne is currently testing its electrodes for long term
stimulation. The Company is also investigating the potential
application of its technology for artificial intelligence and
machine learning. Visit n1mtc.com.
Forward Looking Statements
This press release may
include forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Except for
statements of historical fact, any information contained in this
presentation may be a forward–looking statement that reflects the
Company's current views about future events and are subject to
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some
cases, you can identify forward–looking statements by the words or
phrases "may," "might," "will," "could," "would," "should,"
"expect," "intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target," "seek,"
"contemplate," "continue, "focused on," "committed to" and
"ongoing," or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Forward–looking statements may include statements regarding
potential of our technology to reduce the number of
hospitalizations, surgical procedures and reduce costs. Although
the Company believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our technology will not perform as expected
based on results of our pre-clinical testing; uncertainties
inherent in the development process of our technology; risks
related to changes in regulatory requirements or decisions of
regulatory authorities; risks that we may not have accurately
estimated the size and growth potential of the markets for our
technology; and other risks and uncertainties related to market and
other conditions, the impact of general economic, industry or
political conditions in the United States or
internationally and those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of the press release and the Company undertakes no obligation
to revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-its-disruptive-next-generation-diagnostic-electrode-technology-at-the-noblecon18-investor-conference-on-april-20-2022-301526824.html
SOURCE NeuroOne Medical Technologies Corporation